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recommendations, which will enable me to deliver the best possible care to those patients in need 
of excellent COPD management.  My hope is that this study will lead to future studies, as well as 
practice change, and improved outcomes of the COPD patients of Norton Healthcare and perhaps 
beyond.
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Abstract 
Background: Chronic obstructive pulmonary disease (COPD) is a leading cause of death in the 
United States (U.S), with rates in Kentucky among the highest in the nation.  Quality care in the 
primary care setting is key to optimizing the health outcomes of those with COPD. 
Purpose: The objective of this study was to establish a baseline of COPD patient care in a 
primary care clinic.  The specific aims of this study were to: 1) describe the demographic and 
health-related characteristics of patients with COPD who have a primary care provider (PCP) at 
one Norton Healthcare primary care clinic; 2) explore relationships among key variables; and, 3) 
evaluate provider adherence to COPD evidence-based practice (EBP) guidelines. 
Methods: The study was conducted as a retrospective chart review, including a sample of 
patients (N=215) from the clinic between January 1, 2015 and December 31, 2015.   
Results: Tobacco smokers have more exacerbations than former and never smokers; those with a 
heart failure (HF) comorbidity were more likely to have had a COPD exacerbation, and were 
more likely to be hospitalized with a COPD exacerbation; and, those with a diabetes mellitus 
(DM) comorbidity were also more likely to be hospitalized with a COPD exacerbation. The 
studied clinic did not meet national benchmarks for bronchodilator therapy, timely PCP follow-
up after hospital discharge, or readmission rates.  
Conclusion: The results of this study indicate a need for a practice improvement intervention 
involving program implementation to reduce hospitalizations.  Specific aims of the program 
include: 1) spirometry evaluation in the clinic for objective diagnosis and staging of COPD; 2) 
optimizing the electronic medical record (EMR) with the addition of COPD templates; and, 3) 
creating a process for timely follow-up after hospital discharge, particularly for patients with HF 
or DM.   
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Baseline of COPD Management in a Norton Healthcare Primary Care Clinic 
Background 
 Chronic Obstructive Pulmonary Disease (COPD) is a leading cause of death in the United 
States.  Death rates for stroke and heart disease have significantly declined over the last 10-20 
years, while death rates for COPD have steadily increased (Kochanek, Murphy, Xu, & Tejada-
Vera, 2016).  United States healthcare costs attributed to COPD in 2010 were $32.1 billion, and 
are projected to be $49 billion by year 2020 (Centers for Disease Control and Prevention [CDC], 
2014).  The National 2010 healthcare costs associated with COPD were paid mostly by state 
federal and state funds (51% by Medicare, 25% by Medicaid), with only 18% by private 
insurance (CDC, 2014).   
 Kentucky is among the states with the highest rates of COPD in the nation, with a near 
15% rate in those over age 55 (National Institutes of Health, National Heart, Lung, and Blood 
Institute [NHLBI], 2012).  The rate of readmission within 30 days for COPD is between 16.3% - 
28% nationally, with Louisville, Kentucky among those with the highest rates from July 2012 – 
June 2013 (Centers for Medicare and Medicaid Services [CMS], 2014).   
 The Triple Aim Initiative of the Institute for Healthcare Improvement ([IHI], 2016) 
includes: 1) the improvement of patient care experience; 2) the improvement of population 
health outcomes; and, 3) the reduction of healthcare costs.  Targeting improvements in the 
medical management of COPD can specifically address all three components of the Triple Aim.  
A CMS prevention quality indicator (PQI) points to COPD as a disease (along with asthma) that 
can be controlled in an outpatient setting, with the claim that high-quality outpatient care reduces 
preventable hospital admissions (CMS, 2016).  Hospital admission and readmission rates above 
national average would suggest a need for improvement in the outpatient management of COPD.   
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Practice Guideline Overview 
The leading evidence-based COPD clinical practice guideline is the Global Strategy for 
the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (Global 
Initiative for Chronic Obstructive Lung Disease [GOLD], 2015).  Goals for treatment in the 
management of stable COPD are to reduce symptoms of COPD and reduce the risk of COPD 
exacerbation.  The presence of certain disease comorbidities change the risk for COPD events 
and have a negative impact on disease prognosis and health outcomes, and are therefore given 
consideration in the guidelines (GOLD, 2015).   
To make a clinical diagnosis of COPD, the guideline clearly states that spirometry is 
required, with a resulting post-bronchodilator forced expiratory volume/forced vital capacity 
ratio (FEV1/FVC) less than 70% (<0.70).  Treatment recommendations are based on severity of 
COPD and impact on patient health status, including risk for exacerbations, hospitalization, or 
death.  The GOLD combined assessment of COPD categorizes people A through D, according to 
subjective and objective assessment results, with groups C and D being high risk for 
exacerbation and poor health outcomes.  Subjective assessment is measured by scores on an 
evidence-based survey, objective assessment is based on spirometry findings, and the final 
category regards exacerbations per year (< 1 or > 2), which is the only measure of assessment 
applicable to this study.   
 Pharmacologic treatment recommendations are based on the group in which the patient is 
categorized.  Table 1 lists the first line long-term pharmacologic recommendations, which are 
based on severity of disease or rather, whether patient fits into patient group A, B, C, or D.  The 
types of medications listed in the table include: short-acting anticholinergic (SAA), short-acting 
beta2-agonist (SABA), long-acting anticholinergic (LAA), long-acting beta2-agonist (LABA), 
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and inhaled corticosteroid (ICS).  In the event of an exacerbation, the goal is to minimize 
exacerbation impact and prevent subsequent exacerbations.  Treatment preference for 
exacerbation includes SABAs with or without SAAs, with systemic corticosteroids and 
antibiotics often being indicated, depending on symptom severity (GOLD, 2015).  There is 
substantial evidence to support primary care management of COPD per GOLD (2015) 
recommendations, however, there is little research specific to patient outcomes related to 
implementation of GOLD recommendations in the primary care setting.   
Purpose 
 The purpose of this study was to establish a baseline of COPD patient care in a primary 
care clinic to inform quality improvement initiatives to reduce preventable hospitalizations for 
COPD.  The specific aims were to:  
1. Describe demographic and health-related characteristics of all specified patients of the 
Norton primary care clinic with COPD during January 1, 2015 through December 31, 
2015. 
2. Explore relationships among key variables (eg. comorbidities and COPD 
exacerbations).   
3. Evaluate provider adherence to GOLD (2015) guideline recommendations.  
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Methods   
Setting and Sample 
 The application to perform this retrospective chart review was approved by the 
Institutional Review Board (IRB) of the University of Kentucky and the Norton Healthcare 
Office of Research Administration (NHORA).  The setting for this study was a primary care 
clinic of Norton Healthcare, located in Louisville, Kentucky.  Subjects of the study included the 
entire population of patients (N=215) who met study inclusion criteria between January 1, 2015 
and December 31, 2015.   
 Inclusion criteria consisted of the following: age 40 or older; had an outpatient visit 
(addressing COPD) to the clinic between January 1, 2015 and December 31, 2015; and, had a 
PCP at the clinic.  Diagnostic codes included were: International Classification of Disease Ninth 
Edition (ICD-9), 490, 491, 492, 494, 496; ICD Tenth Edition (ICD-10) J44.0, J44.1, J44.9; and, 
Medicare Severity Diagnostic Related Groups (MS-DRGs) 190, 191, 192, 202, or 203.  
Exclusion criteria included: under 40 years of age; without an outpatient visit addressing COPD 
diagnosis or symptom management between January 1, 2015 and December 31, 2015; became 
patient of the clinic after January 1, 2015; employee of the Fincastle clinic; and/or, personal 
acquaintance or associate of the principal investigator (PI).  
Data Collection 
Norton Health Information Management (HIM) personnel provided a report based on 
study inclusion criteria.  An electronic crosswalk table data collection tool was assembled to 
simplify the data collection process. The variables for data collection are within the results 
section and tables within the Appendix of this manuscript.  All data was collected through Epic 
(Epic Hyperspace, Released 2015), the electronic medical record (EMR) platform used by 
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Norton Healthcare.  The data was entered into the data collection tool, with all data analyzed 
through the IBM SPSS program (SPSS Version 22, Released 2013). 
Statistical Analysis 
Descriptive statistical analysis was used to summarize the data within IBM SPSS (SPSS 
Version 22, Released 2013).  Non-parametric statistical analyses were used to evaluate 
relationships and establish correlations between variables.  Bivariate analyses were used to 
evaluate relationships between two variables.  Chi-square test for independence was used to 
discover relationships between two nominal or categorical variables.  The Mann-Whitney U 
tested for group differences between nominal and ordinal variables, including mean rank and 
median comparisons.  Spearman’s Rank Order Correlation (Spearman’s rho) tested for 
correlation between two ordinal variables.  Statistical significance was determined by a p value 
less than or equal to 0.05 (p=<0.05).  If significant, the effect size was defined as small (r=0.10 
to 0.29), medium (r=0.30 to 0.49), or large (r=0.50 to 1.0) based on the widely accepted Cohen 
(1988) guidelines outlined in the SPSS text (Pallant, 2013). 
Results 
 The study sample included 215 patients aged 41 to 94 years, with a median age of 65.  
Tables 2, 3, 4, and 5 demonstrate the detailed results from the study.  In summary, most patients 
were white (66%) or black (34%), and the gender studied was mostly female (67%) versus male 
(33%).  Most of the patients in this sample were current smokers (52%) or former smokers 
(43%).  The four categories for insurance type were Medicare (65%), Medicaid (24%), 
commercial or private (10%), and other or no insurance (1%).  Figure 1 illustrates that the payer 
distribution for this study is consistent with the 2010 national data reported by the CDC (2014).  
Table 6 demonstrates the findings that insurance type was not correlated with COPD 
  
7 
 
hospitalizations or readmissions.  Commercial or private insurance was not presented in this 
table due to an inadequate sample size for testing. 
Exacerbations 
 
There were 45 (21%) people in the study (N=215) who had at least one exacerbation, and 
20 (9%) with two or more over the 12-month study period.  Additional exacerbation data is 
displayed in Table 2.  Spearman’s rho identified a statistically significant (p=0.037) relationship 
when testing for correlation between smoking status and number of COPD exacerbations.  There 
is a positive correlation of small effect size (r=0.142), indicating that current smokers have more 
exacerbations than the former and never smokers.  The only comorbidity that correlated with 
COPD exacerbation was HF, which will be discussed further in the comorbidities subsection.     
Primary Care Provider and Emergency Department Visits 
 Data regarding visits to the clinic PCP, Norton emergency department (ED), and Norton 
hospitals is displayed in table 2.  Most people (56%) had four or more PCP visits over the 12-
month period.  Very few people had ED visits for COPD (<5%), however, the study was limited 
to Norton ED visits only, and there are several other ED options within proximity to Norton ED 
locations.  About 27% of patients had ED visits for reasons other than COPD, however, the 
specific reasons were not part of the study.  No statistically significant relationships could be 
found between number of PCP visits, ED visits or hospitalizations.  Table 7 displays the 
variables, p value, and the testing method compelling this conclusion. 
Pharmacotherapy 
 
 Data was collected by type of medication and whether it was used for long-term disease 
management, versus only used in times of exacerbation.  The data collected on long-term 
pharmacotherapy is reported in frequency and rate in table 2.  Those with two or more (> 2) 
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exacerbations per year are considered high-risk per GOLD (2015) measures, which places 20 
(9%) patients from the study group (N=215) into patient Group C or D (see table 1 for grouping).  
The recommended long-term medication options for Group C and D patients include: LAA only, 
or ICS plus (+) LABA, or ICS + LABA + LAA.  Figure 2 displays the medication combinations 
used for the high-risk patients (n=20), and identifies an 85% compliance rate with recommended 
long-term pharmacotherapy based on disease severity category.  
 Physician Quality Reporting System (PQRS) Performance Measure #52 is regarding 
bronchodilator therapy for all patients with COPD (CMS, 2016).  The 2014 benchmark for 
bronchodilator therapy was reported at 92%.  This performance measure for bronchodilator 
therapy aligns with GOLD recommendations.  This study found an 83% rate of long-term 
bronchodilator therapy among the sample. 
 Standards of care for exacerbation treatment includes adding or increasing SABA and 
SAA inhaled medications, and adding systemic antibiotic and/or systemic corticosteroid in some 
cases, when appropriate.  This study included antibiotic and corticosteroid administration as 
variables for collection regarding exacerbation.  Medication use across the entire sample 
(N=215) is displayed in Table 2, and medications for exacerbation are in Table 8.  There were 45 
people (n=45) who had at least one exacerbation among the population (see data in table 2).  Due 
to data extraction difficulty, the addition of or increase in SABA and SAA medications as well as 
indications for use of steroid and antibiotic medications were not study variables.  Therefore, the 
table 8 shows whether the patient with an exacerbation had SABA and/or SAA as long-term 
medications, and whether systemic antibiotic and/or corticosteroid were additional exacerbation 
treatments.  All but two people (4%) in the group (n=45) were treated with one of the four 
recommended medication combinations, thus, a 96% compliance rate with recommendations for 
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exacerbation treatment was found.  Most patients were treated with inhaled medication (SABA 
and/or SAA) and both systemic antibiotic and systemic steroid therapy (56%). 
Comorbid Conditions  
 There were nine comorbid conditions tracked, with a median number of two 
comorbidities per patient (N=215).  The comorbidities tracked in the study include: anxiety 
and/or depression; atrial fibrillation (Afib); cognitive impairment; diabetes mellitus (DM); 
gastroesophageal reflux disease (GERD); heart failure (HF); hypertension (HTN); lung cancer; 
and, osteoporosis.  Comorbidity frequencies and rates are displayed in table 2.  The occurrence 
rate of the top five occurring comorbidities is illustrated in figure 3, while figure 4 illustrates the 
number of comorbidities present in each study subject.  
 Number of COPD exacerbations and presence of HF comorbidity were found to be 
related.  A Mann-Whiney U test revealed (U=2206.500, z=-3.412, p=0.001, r=-0.233) a 
statistically significant difference of small effect size, in the number of exacerbations in those 
who had HF (n=33).  Therefore, those with HF (mean rank=132.14) were slightly more likely to 
have had a COPD exacerbation than those studied (N=215) who did not have HF (mean 
rank=103.62).   
 A Mann-Whitney U test revealed (U=1144, z=-3.142, p=0.002, r=-0.214) a statistically 
significant difference of small effect size, in the number of comorbidities in those who had a 
hospitalization for COPD (n=20, median=3 comorbidities) and those who did not have a 
hospitalization for COPD (n=195, median=2 comorbidities).  These findings indicate that the 
more comorbidities a person has, the more likely they are to be hospitalized with a COPD 
exacerbation.   
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 When examining each comorbidity in a Chi-square test for independence, HF and DM 
were the comorbidities found to relate to hospitalization for COPD exacerbation.  Those with 
DM (n=68) were found to have a statistically significant (p=0.002) relationship of small to 
medium effect size (r=0.230).  Those with HF (n=20) were found to have a statistically 
significant (p=0.000) relationship of medium effect size (r=0.308).  Therefore, those with HF or 
DM were more likely to have a hospitalization for COPD exacerbation than those without HF or 
DM.  No other comorbidities showed statistically significant relationships with hospitalizations, 
however, some did not meet minimal sample size requirement for n.   
 Evidence points to association between anxiety and/or depression, and poor COPD 
prognosis; with both anxiety and depression associating with younger age, female gender, 
smoking, and lower FEV1 (GOLD, 2015).  This study was not able to correlate the comorbidity 
of anxiety and/or depression with female gender (p=0.271), smoking status (p=0.223), 
hospitalizations for COPD (p=0.058), or other hospitalizations (p=0.394).  Presence of anxiety 
and/or depression was found to correlate with younger age (p=0.00), with the median age range 
of 51-60 in patients with this comorbidity (n=97). 
Summary of Hospital Admissions 
 Rather than evaluating hospitalizations only in terms of patients hospitalized (n=20), each 
hospitalization (n=39) was also evaluated separately.  As displayed in table 2, hospitalizations 
were divided into two groups: hospitalization with COPD exacerbation; and, hospitalization for 
anything other than COPD exacerbation.  Both types of hospitalizations were subdivided into 
four groups per number of hospitalizations: zero; one; two; three; and, four (the maximum 
occurring number).  For COPD exacerbation, there was a total of 39 hospital visits distributed 
among 20 patients in the study group. Table 3 reports frequencies and rates of the six variables 
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unique to hospitalizations with COPD exacerbation diagnoses (n=39): length of stay (LOS), 
discharge disposition, follow-up PCP appointment in place at time of discharge (PCP 
appointment at discharge), time from discharge to follow-up appointment (time to appointment), 
time from discharge to follow-up visit (time to actual PCP visit), and readmitted within 30 days 
of discharge for COPD (COPD readmission).   
 The median LOS was four days, with 87% of the group (n=39) having an LOS of seven 
days or less.  Discharge to home was the median and mode (69%) discharge disposition.  Most 
patients (67%) had an appointment with their PCP in place at time of discharge.  However, there 
is no indication in Epic when this appointment was made, thus, the appointment could have been 
made without regard to hospitalization at the last PCP visit.  This might explain why in 22 cases 
(54%), the appointment was scheduled greater than 14 days following hospital discharge.  In 
44% of cases, patients had an actual PCP visit within 14 days; while 56% either had a visit 
greater than 14 days from discharge, were readmitted to the hospital (28%) for COPD, or were 
readmitted for something else (3%).  Readmission for COPD exacerbation occurred 11 times 
(28%) among seven patients.  Among the patients hospitalized for COPD (n=20), seven (35%) 
were readmitted at least one time for COPD.  Readmission for reasons other than COPD 
occurred one time (3%).  It is unclear whether an intervention occurred to schedule PCP 
appointments prior to hospital discharge.  The variation in time from scheduled appointment and 
actual visit might be explained by a care management or nurse navigator intervention (e.g. a 
post-discharge phone call) to move the appointment time closer to the discharge date. 
 Among the hospitalizations (n=39), there were 11 readmissions (n=11) for COPD 
distributed among seven total patients.  Table 4 displays the basic demographic variables and 
results for only the patients who had a COPD readmission (n=7).  Additionally, the data specific 
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to hospitalization for those patients is best viewed in a table comparing the initial hospitalization 
with the subsequent readmissions, as in table 5.  With such a small sample size of people who 
were readmitted (n=7), it is difficult to determine relationships, therefore, the data is reported in 
frequencies.  Findings of interest include: in hospitalized patients (n=20) the median number of 
exacerbations in hospitalized patients was two, whereas in readmitted patients (n=7) the median 
was three; and, the median number of comorbidities in hospitalized patients was three, whereas 
in readmitted patients the median was four.  Another interesting finding was that there was little 
difference between time to follow up visit between the two groups of hospitalizations.  The 
median time from discharge to PCP follow-up in all COPD hospitalizations (n=39) was >14 
days, and for the readmissions (n=11), it was 11-14 days.  Readmitted patients having a higher 
number of comorbidities indicates they could be more ill and at higher risk for exacerbation than 
those who were not readmitted.  The minimal difference in time to follow-up indicates there 
might have been an intervention, but there is room to improve in the higher risk patients. 
Comparison of Data 
  One study concludes that highest risk patients should follow-up within seven days from 
hospital discharge (Jackson et al., 2015); however, other study recommendations vary according 
to risk and diagnosis.  Timeliness is not specifically defined as a national best practice 
recommendation, therefore, this study focused on 14 days or less for comparison with reported 
data.  Hospital compare (CMS, 2016) reports 2012 – 2015 readmission rates for both Norton 
Healthcare and the nation of 20%.  The hospitalizations in this study group (n=39) had a 
readmission rate of 28%, indicating a performance worse than national and Norton averages.    
 Follow-up rates within 14 days of hospital discharge are compared in figure 5.  
Comparisons are of the hospitalizations of this study group (n=39), with reported national and 
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Norton Healthcare averages for HF (The Dartmouth Institute for Health Policy and Clinical 
Practice [DAHC], 2016).  No data could be found on COPD specifically for this measure, thus, 
HF was used for comparison.  Figure 5 shows that COPD patients of the study have lower rates 
of PCP follow-up within 14 days of discharge than Norton Healthcare and the nation (for HF 
hospital discharges), indicating performance below the national standard. 
 All identifiable significant relationships among variables were summarized in this results 
section.  There were 39 hospitalizations distributed among 20 patients, and there were 11 
readmissions for COPD, distributed among seven patients.  When testing for relationships 
between COPD hospitalization variables and others, specific patients with a COPD 
hospitalization were compared (n=20), thus making for a smaller sample for comparison.  
Variables were often manipulated and recoded from ordinal variables into bivariate nominal 
variables to enable various testing methods.  The variables of interest in which there were no 
identifiable relationships are reported in Table 9, along with p-values and testing methods.  
Listed variables in table 9 are as follows: smoker (yes or no), smoking status (current, former, or 
never), any hospitalization (ordinal range), any hospitalization status (yes or no), COPD 
hospitalization (ordinal range), COPD hospitalization status (yes or no), readmission (yes or no), 
number of comorbidities (ordinal range) number of PCP visits (ordinal range), ED for COPD 
(ordinal range), ED for other than COPD (ordinal range), number of comorbidities (ordinal 
range), PCP appointment at discharge (yes/no), follow-up visit within 14 days of discharge (yes 
or no). 
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Discussion  
 An exhaustive literature review of published studies has determined that this is the first 
time an attempt has been made to establish a baseline of primary care management of COPD in 
the U.S. per the updated GOLD (2015) guideline recommendations.  This study was a 
retrospective chart review conducted through the Epic EMR that included patients with COPD 
(N=215) who had a visit within the 12 months of 2015 to the Norton Healthcare primary care 
clinic studied.  This study aimed to describe the characteristics of those studied, explore 
relationships among key variables, and evaluate provider adherence to GOLD (2015) guideline 
recommendations.   
 The first aim of this study was met by providing a description of the sample 
demographics and health characteristics of the COPD patients in the Louisville, Kentucky 
primary care clinic (N=215).  The sample was majority white (65%), female (67%), current 
smokers (52%), with a median age of 65.  The payer distribution was divided among Medicare, 
Medicaid, and commercial payers at a rate consistent with national rates.  Resulting frequencies 
and rates of data regarding demographic variables, exacerbations, outpatient and inpatient visits, 
COPD pharmacotherapy, and comorbid conditions is displayed in table 2.   
 The significant relationships found were related to risk for exacerbation and 
hospitalization.  Statistically significant relationships regarding exacerbations included: current 
smokers have more exacerbations than former and never smokers; those with HF tend to have 
more COPD exacerbations than those without HF; those hospitalized with COPD exacerbation 
tend to have more comorbidities than those who were not hospitalized; and, those with HF or 
DM comorbidities are more likely to be hospitalized with COPD exacerbation.  These findings 
are not surprising, as it is widely accepted as fact that tobacco smoking is a risk factor for COPD 
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and continued smoking in presence of COPD leads to more complicated and rapid disease 
progression (GOLD, 2015).  Studies have also established a connection between HF and COPD 
exacerbations and hospitalizations, and indicate that it can be difficult to separate cause of 
exacerbation with concomitance of HF and COPD due to both being diseases of exacerbation 
and remission (Iversen et al., 2008).    
 With the connection between cardiovascular disease and lung disease, and DM and 
cardiovascular disease (Mannino, Thorn, Swenson, & Holguin, 2008;) (GOLD, 2015), it is also 
not surprising that a DM comorbidity is associated with higher risk of hospitalization for COPD 
exacerbation.  This study finding a relationship between a higher number of comorbidities and a 
higher incidence of COPD hospitalization correlates with the previously established evidence 
(GOLD, 2015). 
 Another aim of this study was to determine the degree to which the clinic adhered to 
GOLD 2015 guidelines.  Due to study design, the data collected, and the 2015 structure of the 
Epic EMR, a complete assessment of guideline adherence could not be performed.  Key GOLD 
(2015) recommendations include: diagnostic spirometry evaluation; pharmacologic treatment 
based on severity of disease (determined by spirometry results and symptoms); recommended 
treatment of COPD exacerbations include adding/increasing inhaled SABA and/or SAA, and 
adding systemic antibiotic and/or corticosteroid when appropriate; and, treating comorbidities 
per the practice guidelines for those comorbidities.  Without data collected on evaluation 
procedures on all tracked comorbidities, it cannot be determined whether comorbidities were 
treated in accordance with guideline recommendations. 
 Diagnostic spirometry data was a variable for collection until it was determined that 
spirometry was not done or was not reliably reported in the EMR.  The capability for spirometry 
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use as an objective diagnostic tool was not present on site, and there was no standard location for 
spirometry documentation in the EMR.  The patient burden required an off-site visit at a 
separately scheduled time.  Burden on clinic providers/staff included ordering and submitting 
referrals, obtaining records, and provider review/follow-up.  These factors are highly likely to 
have influenced spirometry evaluation for this population and can easily explain a lack of 
spirometry for diagnosis.  It is also likely that diagnosis of COPD was based on patient-reported 
historical diagnosis and clinical presentation, rather than the diagnostic and staging criteria 
defined by the GOLD 2015 guidelines.  
 The lack of variables to assess exacerbation further inhibited the ability to evaluate 
whether recommendations for exacerbation pharmacotherapy were followed.  However, GOLD 
(2015) and CMS (2016) recommend long-term bronchodilator therapy at stages of disease, with 
2014 national benchmark of 92% compliance.  The study finding an 83% rate of compliance 
with this recommendation indicates room for improvement.  Another method used to determine 
medication compliance was the pharmacologic treatment used in patients who had a COPD 
exacerbation (n=45).  The evaluation indicated that most patients (96%) were treated with GOLD 
recommended therapies.  The patients with two or more exacerbations (n=20) fit into the GOLD 
high-risk grouping C or D; the evaluation of these therapies indicated an 85% compliance rate 
with recommended long-term pharmacotherapy among these patients.  Therefore, through the 
information that is available, it can be stated that the clinic requires improvement in 
bronchodilator therapy to meet the national benchmark.  Without benchmark comparisons for the 
others, it appears acceptable, the compliance rates of 96% and 85% for exacerbation and high-
risk patient treatments respectively.  
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Limitations 
The study had a small sample size overall, in which the entire sample included 215 patients, with 
39 total hospitalizations, and 11 readmissions.  The small size limited the ability to test for 
relationships among variables because the sample sizes were often too small for reliable testing 
and/or had a low power of test results.  The study design did not account for the overlap in 
clinical presentation and treatment recommendations for COPD, asthma, and bronchitis, so 
limiting data evaluation to only COPD exacerbation suggests disease process, specifically 
exacerbations, were underreported in this study.  The collection of data over one year, versus two 
or more years of data limited the ability to grasp the big picture of disease progression and 
disease management.  Tracking exacerbation medications for this study included only the 
addition of systemic corticosteroids and systemic antibiotics.  Additional tracking of SABA and 
SAA use for exacerbations was not done due to overlap with most patients being on long-term 
SABA and/or SAA, and the inability to redesign methods for data collection.  This limited the 
ability to determine compliance with exacerbation treatment. 
Possibly the largest limitation and factor inhibiting the ability to determine guideline 
adherence, was the inability to stage the severity of COPD in the population. Without spirometry 
data, it was impossible to measure guideline adherence due to guideline recommendations being 
largely based on spirometry values.  The study data only being from Norton facilities has an 
unknown impact on the ability to fully appreciate the complete picture of the COPD disease 
process and disease management.  There are several non-Norton options for emergency and 
hospital care in the Louisville area, and patients often require emergent care for COPD 
exacerbations, and thus travel to the nearest medical facility.  Finally, tracking only PCP visits 
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post-discharge versus including specialist visits such as pulmonology visits, might have led to 
underreporting of timely hospital follow-up. 
Practice Improvement Recommendations  
 The NHLBI (2012) reported rate of hospitalization is 15% for Kentucky residents over 
age 55, and the admission rate for COPD of those in this study aged 55 and over was also 15%.  
Considering the CMS (2016) PQI regarding hospital admissions for COPD and asthma, the 15% 
admission rate and 28% readmission rate of those in this study (N=215), targeting a reduction in 
hospitalizations is an appropriate goal for this clinic.  A pilot program to better manage COPD in 
the outpatient setting per GOLD guidelines with the goal of reduction in hospitalizations (and 
readmissions) is the recommendation based on study findings and evidence-based practice 
recommendations.  Program aims include: 1) objective diagnosis and staging of COPD on all 
patients; 2) optimize the EMR with COPD templates; and, 3) create a process for timely follow-
up after hospitalization.   
 Additional study procedure recommendations include: account for specialist visits as data 
variables, particularly pulmonology; include asthma exacerbation and acute bronchitis in 
variables for collection; include all GOLD comorbidities and treatments as variables; collect data 
on smoking cessation counseling and cessation treatments; and, include data regarding timely 
follow-up intervention for those hospitalized with COPD exacerbations.  Comparing the findings 
of this study to those of future years could have broad implications for COPD management in 
primary care.   
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 Timely Follow-up.  Past study findings link timely outpatient follow-up after hospital 
discharge with reduction in readmission rates (Jackson et al., 2015;) (Misky, Wald, & Coleman, 
2010).  Pittsburgh Regional Health Initiative (2011) recommends identifying patients at highest 
risk for readmission and implementing a high-impact intervention that will improve transition 
back to the community and prevent an avoidable hospital readmission.  Jackson et al. (2015) 
found that outpatient follow-up within 14 days of hospital discharge was associated with a 1.5% 
to 19.1% reduction in readmissions, with the wide range due to varying risk groups.  When 
comparing the study population to Norton Healthcare and national averages, the study population 
revealed a comparatively high readmission rate of 28% and a low rate of PCP follow-up within 
14 days of 44%.  Considering previous evidence suggesting the importance of timely follow-up, 
as well as the relationship findings in this study between comorbidities and COPD 
hospitalization, there is evidence that the clinic would benefit from a focus on timely PCP 
follow-up after hospital discharge. 
 The goal includes improving the rate of follow-up within 14 days from 44% to at or 
above 60%.  The proposed intervention to achieve this goal includes the use of the outpatient 
nurse navigator (already in place at the clinic) to ensure that a follow-up appointment is in place 
prior to hospital discharge.  Additionally, this nurse navigator will make a follow-up telephone 
call within two days of hospital discharge to confirm the appointment and assist the patient with 
any health questions or barriers to follow-up.  Due to the study group having a higher-than-
average COPD readmission rate, targeting timely follow-up could serve as a high-impact 
intervention to reduce readmission rates.  Specifically targeting those with HF and DM 
comorbidities could also be impactful due to the relationship between those diagnoses and 
hospital admission rates found in this study.   
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 Staging COPD Severity.  Both GOLD (2015) and CMS (2016) agree that it is a 
diagnostic necessity for patients with COPD to have at least baseline spirometry evaluation.  
Spirometry is a low-cost, billable test that takes minimal time to perform, with results that can be 
immediately interpreted by the PCP.  The proposed intervention includes performing spirometry 
in the clinic.  This will require training medical assistants at test administration, obtaining the 
required equipment, and dedicating a location in the clinic for performing spirometry.  The 
benefits to on-site spirometry evaluation include: a reduction in patient burden due to decreased 
outpatient visits and cost; the results can be interpreted by the PCP immediately following 
testing, therefore objectively guiding treatment per guidelines; and, the clinic will benefit from 
an increased revenue.  
 Medical grade spirometry equipment can be purchased at a cost below $2,000, and 
Medicare reimbursement for various spirometry tests ranges $36-$57 (Jones Medical Instrument 
Company [Jones], 2015; QRS Diagnostics [QRS], 2012).  If equipment is purchased for $2,000, 
with four tests performed weekly, at an average reimbursement of $44 per test, the net revenue 
after one year is $7,152.  In this scenario, the return on investment is achieved in about 11 weeks.  
Best practice recommendations, the results of this study, and spirometry revenues lead to a 
strong recommendation that this primary care clinic have spirometry evaluation capability, 
trained spirometry administrators, and the goal of baseline spirometry evaluation in all patients 
with COPD.  Spirometry and Epic optimization to prompt providers to obtain spirometry 
evaluation is a recommendation based on the existing evidence and findings in this study.    
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 Optimization of the Electronic Medical Record.  Optimization of the EMR is an 
ongoing process at Norton Healthcare, and has not occurred system-wide to specifically target 
COPD management in primary care.  Results from this study indicate need for improvement in 
GOLD (2015) guideline adherence, and the use of EMR templates for chronic disease 
management has been shown to align patient care with EBP guidelines (Gronkiewicz, Borkgren-
Okonek, Diamond, & Hickam, 2009).  The recommended intervention is to implement an 
evidence-based template in the EMR for COPD management in primary care.   
 Recent Epic optimization has occurred to improve DM management per guideline 
recommendations.  This includes a template of best practice recommendations and a standard 
location in which to document DM care.  It is recommended that the COPD template includes 
disease symptoms, spirometry values (and corresponding date), COPD staging, pharmacologic 
treatment regimen, GOLD comorbidities, and dates of recent exacerbations and treatments.  The 
template should also include provider prompts to guide care per recommendations.  The use of 
COPD templates has the potential to improve patient health outcomes, as well as improved 
reported measures such as bronchodilator therapy and spirometry.  An additional benefit of 
optimizing the EMR to include these components, is that it will simplify future studies 
measuring guideline adherence, and change in patient outcomes such as hospitalizations and 
exacerbations.   
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Conclusion 
 The data and analysis regarding hospitalizations and comorbidities have provided 
valuable results with implications for practice improvement and future research.  Results from 
this study indicate that the implementation of evidence-based practice change initiatives will 
improve the health outcomes of patients with COPD.  Implementing the suggested program 
interventions incorporates every aspect of the Triple Aim (IHI, 2016).  The process for timely 
follow-up puts patients at the center of care includes their best interest as well as cost-reduction 
in the efforts to promote health and reduce hospital readmissions.  The spirometry intervention 
will reduce the patient burden of an off-site visit, it will objectively guide treatment to improve 
health outcomes, and will help achieve reduced costs by improving health and reducing both 
outpatient and hospital visits.  Optimization of the EMR with COPD templates will enable 
patients to better report their symptoms, providers to better treat their disease, and improved 
outpatient disease management will be cost-effective in that it will reduce hospitalizations.   
 Professional next steps as a Doctor of Nursing Practice will be to share these study 
findings with stakeholders and obtain buy-in for the pilot program.  It will be necessary to 
explore potential barriers and modify the program to optimize potential outcomes, as well as 
develop an implementation and evaluation method for the proposed program.  Adapting the 2015 
study per previously mentioned criteria will enable 2016 data collection for additional baseline 
data prior to program implementation.  Following at least one year of program implementation, a 
pre-post retrospective study could provide broad implications to inform quality improvement 
initiatives for the management of COPD in the primary care setting.  
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Table 1 
 
GOLD (2015) Pharmacotherapy Management Recommendations for Stable COPD 
 
Patient Group First Line Therapy 
A SAA PRN 
or 
SABA PRN 
B LAA  
or 
LABA  
C ICS + LABA 
or 
LAA 
D ICS + LABA 
and/or 
LAA 
 
Note.  Adapted from GOLD (2015) recommendations.  
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Table 2 
Variables, Measures, and Results for Basic Demographic Data (N=215) 
Variable Frequency Ratea 
Age   
40-50 
51-60 
61-70 
71-80 
81 and over 
19 
60 
62 
45 
29 
9 
28 
29 
21 
14 
Race/ethnicity 
Caucasian/White 
African American/Black 
Other or Unknown 
  
141  
72  
2  
 
66 
34 
1 
Gender 
Female 
Male 
Other 
 
145 
70 
0 
 
67 
33 
0 
Insurance Provider 
Medicare 
Medicaid 
Commercial/Private 
Other or none 
 
139 
52 
22 
2 
 
65 
24 
10 
1 
Smoking Status 
Current (ever smoked in 2015) 
Former (quit prior to 2015) 
Never Smoker 
 
111 
93 
11 
 
52 
43 
5 
Number of exacerbations 
Zero 
One 
Two 
Three 
Four or more 
 
170 
25 
11 
3 
6 
 
79 
12 
5 
1 
3 
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Number of PCP visits 
One 
Two 
Three 
Four or more 
 
18 
41 
35 
121 
 
8 
19 
16 
56 
ED for COPD 
Zero 
One 
Two 
 
205 
7 
3 
 
95 
3 
1 
ED for Other 
Zero 
One 
Two or more 
 
157 
38 
47 
 
73 
18 
9 
Long-Term Pharmacotherapy 
SABA 
LABA 
SAA 
LAA 
ICS 
None 
 
179 
133 
36 
70 
134 
17 
 
83 
62 
17 
33 
62 
8 
Exacerbation Pharmacotherapy 
Both 
Steroid Only 
Antibiotic Only 
Neither 
N/A (no exacerbation) 
 
25 
6 
5 
9 
170 
 
12 
3 
2 
4 
79 
Comorbid conditions  
HTN 
Anxiety and/or Depression 
GERD 
Diabetes 
HF 
Afib 
Osteoporosis 
Cognitive Impairment 
Lung Cancer 
 
160 
97 
71 
68 
33 
22 
15 
11 
5 
 
74 
45 
33 
32 
15 
10 
7 
5 
2 
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Number of hospitalizations – Non-COPD 
exacerbation diagnosis (all other hospitalizations) 
Zero 
One 
Two 
Three 
Four or more 
 
 
166 
30 
10 
3 
6 
 
 
77 
14 
5 
1 
3 
Number of hospitalizations - COPD exacerbation 
Zero 
One 
Two 
Three 
Four or more 
 
195 
9 
4 
6 
1 
 
91 
4 
2 
3 
1 
 
Note.  aRate as percent (%) rounded to nearest whole number.  
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Table 3 
Variables, Measures, and Results for COPD Hospitalizations (n=39) 
Variable Frequencya Rateb 
Length of stay 
Equal to 1 day 
2-3 days 
4 days 
5-7 days 
8-10 days 
11-14 days 
More than 14 days 
 
3 
7 
12 
12 
1 
2 
2 
 
8 
18 
31 
31 
3 
5 
5 
Discharge disposition  
Home 
Home with home health 
Subacute rehabilitation 
Skilled nursing facility 
Pulmonary rehabilitation (outpatient) 
Death prior to discharge 
 
27 
4 
1 
1 
5 
1 
 
69 
10 
3 
3 
13 
3 
PCP appointment at discharge 
Yes 
No 
N/A 
 
26 
12 
1 
 
67 
31 
3 
Time to appointment 
4 days or less 
5-7 days 
8-10 days 
11-14 days 
More than 14 days 
N/A 
 
3 
1 
0 
0 
22 
13 
 
8 
3 
0 
0 
54 
36 
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Time to actual PCP visit 
4 days or less 
5-7 days 
8-10 days 
11-14 days 
More than 14 days 
N/A 
 
7 
5 
2 
3 
10 
12 
 
18 
13 
5 
8 
26 
31 
COPD Readmission 
Yes 
No 
N/A (readmission for non-COPD reason) 
 
11 
27 
1 
 
28 
69 
3 
 
Note.  an = 39 in each variable category.  bRate (%) rounded to nearest whole number and totals per category are 
approximately 100% 
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Table 4 
Variables, Measures and Results for Patients with COPD Readmissions (n=7) 
Variable Frequency 
Age  
40-50 
51-60 
61-70 
71-80 
81 and over 
1 
2 
2 
2 
0 
Race/ethnicity 
Caucasian/White 
African American/Black 
Other or Unknown 
  
2 
5 
0  
Gender 
Female 
Male 
Other 
 
5 
2 
0 
Insurance Provider 
Medicare 
Medicaid 
Commercial/Private 
Other or none 
 
6 
1 
0 
0 
Smoking Status 
Current (ever smoked in 2015) 
Former (quit prior to 2015) 
Never Smoker 
 
5 
2 
0 
Number of exacerbations 
Zero 
One 
Two 
Three 
Four or more 
 
0 
1 
1 
2 
3 
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 Number of PCP visits 
One 
Two 
Three 
Four or more 
 
0 
0 
0 
7 
 ED for COPD 
Zero 
One 
Two 
 
5 
0 
2 
 ED for Other 
Zero 
One 
Two or more 
 
3 
2 
2 
 Long-Term Pharmacotherapy 
SABA 
LABA 
SAA 
LAA 
ICS 
None 
 
7 
6 
4 
4 
5 
0 
Exacerbation Pharmacotherapy 
None 
 
0 
SABA and/or SAA only 0 
SABA and/or SAA  
and Antibiotic 
0 
SABA and/or SAA  
and Steroid  
1 
SABA and/or SAA  
and Steroid 
and Antibiotic 
6 
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Comorbid conditions  
HTN 
Anxiety and/or Depression 
GERD 
Diabetes 
HF 
Afib 
Osteoporosis 
Cognitive Impairment 
Lung Cancer 
 
7 
1 
3 
4 
3 
1 
1 
1 
1 
Number of hospitalizations – Non-COPD 
exacerbation diagnosis (all other hospitalizations) 
Zero 
One 
Two 
Three 
Four or more 
 
 
4 
2 
0 
0 
1 
Number of hospitalizations – COPD exacerbation 
Zero 
One 
Two 
Three 
Four or more 
 
0 
0 
2 
4 
1 
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Table 5 
Comparison of Variables, Measures and Results for Patients with COPD Readmissions (n=7) 
Variable Admissiona Readmissionb Readmissionc Readmissionc 
Length of stay 
Equal to 1 day 
2-3 days 
4 days 
5-7 days 
8-10 days 
11-14 days 
More than 14 days 
 
0 
1 
0 
4 
1 
0 
1 
 
0 
1 
3 
1 
0 
2 
0 
 
1 
0 
2 
2 
0 
0 
0 
 
0 
0 
0 
0 
0 
0 
1 
Discharge disposition  
Home 
Home with home health 
Subacute rehabilitation 
Skilled nursing facility 
Pulmonary rehabilitation (outpatient) 
N/A (death) 
 
3 
2 
1 
0 
0 
1 
 
4 
1 
0 
0 
2 
0 
 
2 
1 
0 
1 
1 
0 
 
1 
0 
0 
0 
0 
0 
PCP appointment at discharge 
Yes 
No 
 
4 
3 
 
5 
2 
 
3 
2 
 
0 
1 
Time to appointment 
4 days or less 
5-7 days 
8-10 days 
11-14 days 
More than 14 days 
N/A (no appointment, death, or 
readmission) 
 
1 
0 
0 
0 
3 
3 
 
0 
0 
0 
0 
5 
2 
 
 
1 
0 
0 
0 
2 
2 
 
 
0 
0 
0 
0 
0 
1 
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Time to actual PCP visit 
4 days or less 
5-7 days 
8-10 days 
11-14 days 
More than 14 days 
N/A (no appointment, death, or 
readmission) 
 
0 
2 
1 
0 
0 
4 
 
 
2 
1 
0 
0 
1 
3 
 
 
2 
0 
0 
1 
2 
0 
 
 
0 
1 
0 
0 
0 
0 
 
COPD Readmission 
Yes 
No 
 
6 
1 
 
4 
3 
 
1 
4 
 
0 
1 
Readmission prior to follow-up visit 
Yes 
No 
 
4 
3 
 
2 
5 
 
0 
5 
 
0 
1 
 
Note.  aColumn total for each section = 7.  bColumn total for each section = 7.  cColumn total for each section = 5.  
dColumn total for each section = 1 
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Table 6 
Relationships Among Insurer and COPD Hospitalization (N=215) 
Variables p-Value Test 
Medicare and COPD hospitalization 
Medicare and COPD readmission 
Medicaid and COPD hospitalization 
Medicaid and COPD readmission 
p=0.301 
p=0.787 
p=0.651 
p=1.0a 
Mann-Whitney U 
Chi-square 
Mann-Whitney U 
Chi-square 
Note.  aMinimum cell count for testing not met. 
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Table 7 
Relationships Among Number of PCP Visits and ED or Hospital Visits (N=215) 
Variables p-Value Test 
PCP and ED COPD p=0.477 Spearman’s rho 
PCP and ED for reason other than COPD p=0.203 Spearman’s rho 
PCP and ED for any reason p=0.492 Mann-Whitney U 
PCP and Hospitalizations for COPD p=0.131 Spearman’s rho 
PCP and Hospitalization for any reason p=0.155 Mann-Whitney U 
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Table 8 
Medications Used in Patients with COPD Exacerbation (n=45) 
Medication Type Frequency Rate (%) 
 
None 
 
 
2 
 
4 
SABA and/or SAA only 
 
7 16 
SABA and/or SAA  
and Antibiotic 
 
5 11 
SABA and/or SAA  
and Steroid  
 
6 13 
SABA and/or SAA  
and Steroid 
and Antibiotic 
 
25 56 
Total 45 100 
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Table 9 
Variables of Interest Without Established Significant Relationships (N=215) 
Variables p-Value Test 
Smoker and COPD hospitalization 
Smoker and readmission  
p=0.197 
p=1.0a 
Mann Whitney U 
Chi-square 
Smoking status and COPD hospitalization p=0.154 Spearman’s rho 
Smoking status and any hospitalization p=0.857 Spearman’s rho 
Number PCP and any hospitalization status 
Number PCP and COPD hospitalization 
Number PCP and ED for COPD 
Number PCP and ED for other 
Number of comorbidities and readmission 
PCP appointment at discharge and readmission 
Follow-up visit and readmission 
p=0.155 
p=0.131 
p=0.477 
p=0.203 
p=0.4 
p=0.396 
p=0.74 
Mann Whitney U 
Spearman’s rho 
Spearman’s rho 
Spearman’s rho 
Mann Whitney U 
Chi-square 
Chi-square 
 
  
  
42 
 
 
 
 
Figure 1.  Comparison of COPD Healthcare Cost Payers 
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Figure 2.  Pharmacotherapy Combinations for High-Risk Patients (n=20) 
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Figure 3.  Occurrence Rate (%) of Top 5 Comorbidities (N=215) 
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Figure 4.  Occurrence Frequency of Comorbidities (N=215) 
 
 
  
9
57
60
59
23
7
0 10 20 30 40 50 60 70
0 Comorbidities
1 Comorbidity
2 Comorbidities
3 Comorbidities
4 Comorbidities
5 Comorbidities
Frequency
  
46 
 
 
 
 
Figure 5.  Patients with a PCP Visit within 14 Days of Discharge 
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